Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

UCB, MRC Technology ink license agreement
March 2014
SHARING OPTIONS:

 
BRUSSELS, Belgium & LONDON—UCB and MRC Technology have launched an exclusive license agreement by which UCB will be granted rights to a novel fibrosis therapy program, which stems from a collaboration between MRC Technology’s Centre for Therapeutics Discovery and academics at the University of Sheffield. Per the agreement, UCB will pay MRC Technology an upfront payment, clinical development milestones and royalties on future products, and in keeping with MRC Technology’s not-for-profit collaborative model, the deal revenue will be shared back with the University of Sheffield and reinvested to support other collaborative programs. Michael Dalrymple, MRC Technology’s director of business development, noted that, “This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.